• Article highlight
  • Article tables
  • Article images

Article History

Received : 03-09-2024

Accepted : 18-10-2024



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 89

PDF Downloaded: 17


Get Permission Ch Marak, Marwein, and Kma: Soy's secret weapon: Genistein's fight against triple-negative breast cancer


Introduction

Cancer remains one of the leading causes of morbidity and mortality worldwide, with its prevalence continuing to soar as the global population ages. As per the Global Cancer Observatory (GLOBOCAN) estimates, 2022 saw approximately 19.9 million new cancer cases globally. Triple-negative breast cancer (TNBC) represents a distinct subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).1 This subtype constitutes around 10-15% of all breast cancer cases and is linked to aggressive tumor behavior, increased rates of metastasis, and a less favorable prognosis compared to other subtypes of breast cancer.2 TNBCs account for approximately 85% of all basal-like tumors. It is a heterogeneous disease with complex molecular features. 3

Figure 1

Comparison of triple-Negative breast cancer (TNBC) with other breast cancer subtypes. In the landscape of breast cancer, TNBC accounts for approximately 15% of cases,

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/b439806a-2c7b-40b2-885e-0f35404ae46aimage1.png

Characterized by its lack of estrogen receptor (ER) and progesterone receptor (PR) expression (ER-/PR-) and human epidermal growth factor receptor 2 (HER2-). Most breast cancer cases fall into the ER-positive (ER+) category, comprising approximately 65 to 75% of cases, where cancer cells express the estrogen receptor. The HER2-positive (HER2+) subtype constitutes approximately 15-20% of cases and is marked by the overexpression of the HER2 protein. TNBC stands out as a distinct subtype due to its unique molecular profile, making it particularly challenging to treat with targeted therapies commonly used for ER+ and HER2+ breast cancers. It is notorious for its aggressive nature, tendency to metastasize, high risk of relapse, and poor prognosis and survival outcomes.

Types and Subtypes of Triple-negative Breast Cancer (TNBC)

Breast cancer is a complex disease with a wide range of gene expression.4 The course of the disease, the outcome of treatment, and patient survival are all determined by this heterogeneity. Breast cancers are divided into two types depending on the presence or absence of the receptors. The presence of one or a combination of estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2) makes some groups of breast cancer more susceptible to targeted hormone/HER2 therapy.5 TNBCs, on the other hand, are breast tumors that lack any of these three receptors.6 Therefore, receptor status has a significant impact on the treatment and prognosis of breast cancer patients.7 TNBC is the most aggressive group of breast cancers with a high recurrence rate and poor prognosis. However, each molecular subtype of TNBC responds differently to treatment and has different clinical outcomes.8 TNBC has been classified into six subtypes based on genomic expression profiling: basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), and luminal androgen receptor (LAR).9

Table 1

Subtypes of triple-negative breast cancer (TNBC) and their haracteristics

TNBC Subtype

Description

Molecular Characteristics

Prognosis

Basal-like

Most common subtype, high-grade, poor prognosis

High expression of cytokeratin’s 5, 6, 17

Poor

Androgen receptor-positive

Expresses androgen receptor, relatively better prognosis

Positive expression of androgen Receptor

Better

Mesenchymal-like

Mesenchymal and stem cell-like features, aggressive phenotype

High expression of mesenchymal and stem cell markers

Poor

Immuno-

Presence of immune-related genes, Potential Response to Immunotherapy

Presence of immune-related genes, immune cell infiltration within tumor

Varies, potential response to immunotherapy

LAR [Luminal Androgen Receptor]

Expresses androgen receptors, luminal features, relatively better prognosis

Positive expression of androgen receptor,

Better

Pathways anomalies in breast cancer/TNBCs

A crucial step in the initiation and development of cancer is cell signal transduction. Tumor cells display distinct features or hallmarks, such as uncontrolled cell growth, genomic instability, and resistance to programmed cell death. These characteristics arise due to modifications in various cellular signaling pathways, which contribute to the enhanced proliferation, advancement, and survival of tumor cells.10 These modifications occur as a result of mutations in oncogenes that lead to excessive protein expression, mutations in proteins that cause unregulated activity, or inactivation of tumor suppressor genes that facilitate these processes.11 As a result, cancer medications essentially target one or more of these signaling pathways. TNBC is associated with the dysregulation of various signaling pathways that contribute to its aggressive behavior and resistance to conventional therapies. Some of the key signaling pathways commonly de-regulated in TNBC are:

    1. Wnt/β-catenin Pathway: Overactivation of this pathway, driven by genes like FZD7 and LRP6, promotes tumor growth and resistance in TNBC.12, 13, 14 Additionally, Nek2B, by interacting with β-catenin, further activates this pathway, leading to a worse prognosis. 15, 16 Targeting these components shows promise in preclinical studies.

    2. Notch Signaling Pathway: High levels of Notch receptors (Notch1-4) and ligands (JAG1, DLL4) are linked to aggressive TNBC. Specifically, high NOTCH1 and JAG1 levels, especially when co-expressed, are associated with poorer survival. Inhibiting Notch1 and JAG1 is a potential therapeutic strategy. 17, 18

    3. NF-κB Signaling: Dysregulation leads to increased expression of genes like CD44 and MMP9, promoting tumor invasion. Inhibiting NF-κB shows promise in reducing TNBC cell growth and invasiveness. 19, 20

    4. PI3K/AKT/mTOR Signaling: This pathway is frequently dysregulated in TNBC, contributing to tumor growth and therapeutic resistance. This can occur through genetic alterations like PIK3CA mutations or PTEN loss.21, 22 Targeting this pathway shows promise; for instance, inhibiting DEK, an oncoprotein that regulates this pathway, reduces TNBC cell migration and angiogenesis.23 Additionally, using AKT inhibitors like ipatasertib has shown promise in clinical trials.24

    5. MAPK (Ras/Raf/MEK/ERK) Signaling: High MAPK activity is linked to a poorer prognosis in TNBC. EGFR overexpression, common in TNBC, can lead to increased MAPK signaling, promoting tumor growth and hormone-independent proliferation.25 Additionally, reactive oxygen species (ROS), often elevated in TNBC, can further activate MAPK.26 Targeting this pathway, perhaps in combination with PI3K pathway inhibitors, is promising, as crosstalk between these pathways can lead to treatment resistance.

Figure 2

Different signaling pathways for survival, proliferation, and metastasis used by TNBC

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/b439806a-2c7b-40b2-885e-0f35404ae46aimage2.png

Genistein and TNBC

TNBC has a lower survival rate and is more likely to return and spread than other subtypes of breast cancer. Historically, chemotherapy was the primary treatment due to the absence of hormone receptors and HER2 amplification.27 However, such a therapeutic strategy is unable to overcome the negative side effects and medication resistance brought on by chemotherapy in cancer patients. Given this situation, investing efforts in researching and developing cutting-edge treatment drugs or interventional techniques that balance high effectiveness and low toxicity for individuals afflicted with TNBC becomes crucial.28 Plant-based chemicals are being studied as potential adjuvants or combination therapies for TNBC. Many bioactive compounds from medicinal plants have shown promising anticancer effects.29 Some of the most highly explored plant compounds having a wide range of therapeutic qualities, including antitumor action, are Flavonoids, carotenoids, alkaloids, and phenolics.30, 31, 32, 33

Among these phytochemicals, Genistein (GEN), also known chemically as 4,5,7-trihydroxy isoflavone, a natural isoflavone found in soybeans and legumes, is a promising phytochemical in cancer research. It has shown potential as a chemopreventive agent, inhibiting cancer cell growth and reducing the risk of certain cancers, particularly breast and prostate cancer in Asian populations.34 Genistein's impact on breast cancer is significant because it interferes with estrogen, a key player in cancer development, by binding to estrogen receptors (ER).35 It competes with 17β-estradiol, demonstrating a 4% binding affinity for ER-α and 87% for ER-β, making it a valuable component in hormone-related cancer treatment.36

Plants have served as natural remedies for centuries. 37 A diet rich in vegetables, fruits, and legumes contains high levels of antioxidants that protect against the harmful effects of free radicals that can lead to the development of cancer. 38, 39 TNBC accounts for approximately 15% of all breast cancers and cannot be treated with targeted drugs commonly used for other types of cancer treatment. Treatment options are limited due to the lack of targeted therapies compared to other types of breast cancer. Dietary GEN, a naturally occurring compound derived from soy and renowned for its flavone properties, has been postulated as the underlying catalyst for the remarkably low incidence of breast cancer among Asian women. 40

In vitro studies

The MDA-MB-231 cell line is an invasive and aggressive breast cancer cell line that does not express ER, PR, or HER2. As a result, this cell line is known as a TNBC cell line. 41 There are few clinically effective treatments for TNBC. To better understand the molecular causes of this kind of breast cancer and to develop novel therapeutic approaches the MDA-MB-231 cell line is often used. In TNBC, GEN downregulates cyclin B1, Bcl-2, and Bcl-xL expression in MDA-MB-231 cells, potentially by inhibiting NF-κB via the Notch-1 pathway. SiRNA-mediated knockdown of Notch-1 or NF-κB also leads to downregulation of cyclin B1, Bcl-2, and Bcl-xL, resulting in G2/M cell cycle arrest and TNBC cell death. 42 Concentration-dependent treatment with GEN also led to the suppression of MEK5, total ERK5, and phospho-ERK5 proteins. This led to reduced NF-κB/p65 levels and DNA-binding activity, inhibiting cell growth and inducing apoptosis. Furthermore, GEN concentration-dependently reduced anti-apoptotic Bcl-2, increased pro-apoptotic Bax, and triggered caspase-3 cleavage and activity. 43 Gel shift assays revealed a cross-talk between NF-κB and Akt signaling pathways, with Akt cDNA transfection inducing NF-κB DNA-binding activity. Additionally, genistein counteracted EGF and Akt-induced NF-κB activation. These findings suggest that genistein's inactivation of NF-κB in MDA-MB-231 breast cancer cells is partly mediated by the Akt pathway.44

GEN was shown to inhibit the progression of MDA-MB-231 breast cancer cells, regulate apoptosis-related gene expression, and promote apoptosis via a p53-independent pathway. Upregulation of Bax and p21WAF1 might be molecular mechanisms by which GEN triggers apoptosis. 45 GEN treatment of MDA-MB-231 cells affects multiple cell cycle processes, including DNA replication, cohesin complex cleavage, and kinetochore formation. Additionally, it activates the DNA damage response, involving ATR and the BRCA1 complex. 46 GEN also shows strong binding to PTEN, an important player in the PI3K pathway in TNBC. When compared to the FDA-approved drug Olaparib using advanced analysis techniques, Genistein exhibits more favorable binding dynamics with PTEN compared to PTEN-Olaparib.47

Fatty acid oxidation (FAO) is vital for TNBC metabolism, fueling their growth, invasion, and metastasis.48 CD36, a key fatty acid receptor, plays a crucial role in this process. 49 GEN treatment reduces CD36 expression and activates p38 MAPK. Combining NP-siCD36 with lower GEN doses effectively hampers MDA-MB 231 cell growth, promoting cell death via the CD36/phospho-p38 MAPK pathway. 50 Furthermore, miR-155 a key player in regulating over 100 cancer-related pathways and cell cycle regulators, and its link to TNBC is well-established. 51, 52 Treatment with GEN has shown to decrease miR-155 expression in TNBC cells. This reduction triggers an increase in miR-155's target genes, including FOXO3, PTEN, casein kinase, and p27, leading to an anti-proliferative and proapoptotic effect in these cells.53

In vivo studies

In ERα-negative MDA-MB-231 xenograft mice, GEN could reactivate ER expression, and this effect was synergistically increased when paired with the HDAC inhibitor trichostatin A (TSA). The GEN therapy also restored ER-dependent cellular sensitivity to the antagonist tamoxifen (TAM) and activator 17-estradiol (E2). Additional research has shown that GEN can cause remodeling of the chromatin structure in the ER promoter, which aids in the reactivation of the ERα. 54 In vivo studies have also shown that lifelong GEN-rich diets, from conception onward, reduce CpG methylation in the BRACA1 gene in female mouse mammary glands. This leads to an increase in BRCA1 expression, restoring ERα expression in TNBC cells and enhancing sensitivity to antiestrogen 4-OHT.55

Moreover, co-administering GEN along with drugs like methotrexate, eicosapentaenoic acid, topotecan, centchroman, 56, 57, 58, 59 and additional combination with phytochemicals such as capsaicin and sulforaphane 60, 61 was observed to showcase remarkable synergy in terms of its impact on TNBC cells and various other forms of cancer. This remarkable revelation suggests that the efficacy of targeting multiple oncogenic pathways can be greatly enhanced by employing combinations of drugs rather than relying solely on the administration of a single monotherapy.

Figure 3

Different Molecular Targets of Genistein on TNBC. In vitro studies using the MDA-MB-231 cell line, a TNBC model, reveal that GEN downregulates key proteins (cyclin B1, Bcl-2, and Bcl-xL) involved in cancer progression, this effect is mediated via the NF-κB/Notch-1 pathway, resulting in G2/M cell cycle arrest and TNBC cell death. GEN inactivation of NF-κB is partly mediated by the Akt pathway. The upregulation of Bax and p21WAF1 seems to be the key molecular mechanisms behind GEN-induced apoptosis. Additionally, GEN shows strong binding to PTEN, an important player in the PI3K pathway in TNBC. Also, treatment with GEN has been shown to decrease miR-155 expression in TNBC cells. This reduction triggers an increase in miR-155's target genes, including FOXO3, PTEN, casein kinase, and p27, leading to an anti-proliferative and proapoptotic effect in these cells. GEN treatment lowers CD36 a key fatty acid receptor and activates p38 MAPK. Combining NP-siCD36 with GEN at lower doses effectively hinders MDA-MB 231 cell growth, triggering cell death via the CD36/phospho-p38 MAPK pathway. In ERα-negative MDA-MB-231 xenograft mice, GEN could reactivate ER expression, and this effect was synergistically increased when paired with the HDAC inhibitor trichostatin A (TSA). Lifelong GEN-rich diets in mice reduce BRCA1 gene methylation, increase BRCA1 expression, restore ERα expression in TNBC cells, and boost sensitivity to the antiestrogen 4-OHT. Lastly, Co-administering GEN with various drugs and phytochemicals shows synergistic effects on TNBC cells and other cancer types, emphasizing the potential of combination therapies.

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/b439806a-2c7b-40b2-885e-0f35404ae46aimage3.png

Conclusion and Future Challenges

To this day TNBC remains a major challenge in breast cancer treatment. TNBC is a difficult subtype to treat due to its aggressive nature, lack of targeted therapy options, and high risk of recurrence and metastasis. 62 Despite these challenges, significant progress has been made in understanding the biology of TNBC and identifying potential therapeutic strategies. Research efforts have focused on exploring new therapeutic approaches such as immunotherapy, targeted therapy, and combination therapy. 63 In this review, we discussed the plant-derived compound GEN which have been demonstrated to have a strong anti-cancer effect in TNBC models in preclinical investigations. GEN primary molecular targets in breast cancer cells seem to be the NF-κB and Akt pathways.44 In vivo studies on mice also suggest that lifelong GEN-rich diets reduce methylation in the BRCA1 gene, potentially restoring ERα expression in TNBC cells and improving sensitivity to antiestrogen treatments.54 Moreover, combining GEN with various drugs and phytochemicals has shown synergistic effects against TNBC and other cancers, highlighting the potential of targeting multiple pathways simultaneously.64 This multifaceted approach holds promise for more effective TNBC treatment strategies. Studies have shown that Asian women who consume 20-50 times more genistein isoflavone-rich soy products per capita than their Western counterparts have a considerably lower risk of developing breast cancer.65, 66

In summary, Genistein holds promise for novel TNBC treatments, but challenges like dose formulation, bioavailability, interactions, and varying responses exist. To optimize its chemical efficacy, future research should explore mechanisms, conduct clinical trials, and investigate combination therapies. Collaboration between doctors, researchers, and patients is vital for advancing our understanding and treatment of TNBC, a highly aggressive form of breast cancer. Interestingly, nanoparticles may offer new prospective TNBC therapeutic options, and nano biosensors may be used as future TNBC diagnostics. Further research might guarantee that the efficacy of present medicines is monitored and that novel therapeutic options to treat TNBC, a disease with a bad prognosis, are discovered. This deep dive into the world of genistein has revealed its exciting potential in the fight against TNBC. While we've seen promising results in the lab, we need to bridge the gap to real-life patients. Robust clinical trials will be key to unlocking genistein's full potential, determining the ideal dosages, and understanding how it can best work alongside existing therapies. The journey ahead is filled with hope, and with continued research, genistein could become a powerful ally for those facing TNBC.

Conflict of Interest

None.

Source of Funding

None.

References

1 

V Minckwitz G Martin Neoadjuvant Treatments for Triple-Negative Breast Cancer (TNBC)Ann Oncol201223359

2 

P Zagami LA Carey Triple Negative Breast Cancer: Pitfalls and ProgressNPJ Breast Cancer202281110

3 

CK Anders LA Carey Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast CancerClin Breast Cancer2009927381

4 

AG Rivenbark SM Connor WB Coleman Molecular and Cellular Heterogeneity in Breast Cancer: Challenges for Personalized MedicineAm J Pathol20131834111324

5 

A Mohamed K Krajewski B Cakar C X Ma Targeted Therapy for Breast CancerAm J Pathol201318341096112

6 

C Liedtke C Mazouni KR Hess F André A Tordai JA Mejia Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast CancerJ Clin Oncol2008268127581

7 

E Varghese SM Samuel M Abotaleb S Cheema R Mamtani D Büsselberg The “Yin and Yang” of Natural Compounds in Anticancer Therapy of Triple-Negative Breast CancersCancers20181010346

8 

YM Lee MH Oh JH Go K Han SY Choi Molecular Subtypes of Triple-Negative Breast Cancer: Understanding of Subtype Categories and Clinical ImplicationGenes Genom2020421213817

9 

BD Lehmann JA Bauer X Chen ME Sanders AB Chakravarthy Y Shyr Identification of Human Triple-Negative Breast Cancer Subtypes and Preclinical Models for Selection of Targeted TherapiesJ Clin Invest20111217275067

10 

D Hanahan RA Weinberg Hallmarks of Cancer: The Next GenerationCell2011144564674

11 

MA Ortega O Fraile-Martínez Á Asúnsolo J Buján N García-Honduvilla S Coca Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTORJ Oncol2020202092583969258396

12 

CC Liu J Prior DP Worms G Bu LRP6 Overexpression Defines a Class of Breast Cancer Subtype and Is a Target for TherapyProc Natl Acad Sc201010711513641

13 

L Yang X Wu Y Wang K Zhang J Wu YC Yuan FZD7 Has a Critical Role in Cell Proliferation in Triple Negative Breast CancerOncogene20113043443746

14 

TD King MJ Suto Y Li The Wnt/β-Catenin Signaling Pathway: A Potential Therapeutic Target in the Treatment of Triple Negative Breast CancerJ Cell Biochem20121131138

15 

J Lee L Gollahon Nek2-Targeted ASO or siRNA Pretreatment Enhances Anticancer Drug Sensitivity in Triple-negative Breast Cancer CellsInt J Oncol201342383947

16 

H Shen W Yan J Yuan Z Wang C Wang Nek2B Activates the Wnt Pathway and Promotes Triple-Negative Breast Cancer Chemothezrapy-Resistance by Stabilizing β-CateninJ Exp Clin Cancer Res2019381243

17 

M Reedijk S Odorcic L Chang H Zhang N Miller DR Mccready High-Level Coexpression of JAG1 and NOTCH1 Is Observed in Human Breast Cancer and Is Associated with Poor Overall SurvivalCancer Res2005651885307

18 

M Locatelli G Curigliano Notch Inhibitors and Their Role in the Treatment of Triple Negative Breast Cancer: Promises and FailuresCurr Opi Oncol201729641127

19 

C Chetty SK Vanamala CS Gondi DH Dinh M Gujrati JS Rao MMP-9 Induces CD44 Cleavage and CD44 Mediated Cell Migration in Glioblastoma Xenograft CellsCell Signal201224254959

20 

SM Smith YL Lyu L Cai NF-κB Affects Proliferation and Invasiveness of Breast Cancer Cells by Regulating CD44 ExpressionPLoS One201499106966

21 

D Massihnia A Galvano D Fanale A Perez M Castiglia L Incorvaia Triple Negative Breast Cancer: Shedding Light onto the Role of Pi3k/Akt/Mtor PathwayOncotarget20167376071222

22 

H Fang J Xie M Zhang Z Zhao Y Wan Y Yao miRNA-21 Promotes Proliferation and Invasion of Triple-Negative Breast Cancer Cells through Targeting PTENAm J Transl Res20179395361

23 

Y Yang M Gao Z Lin L Chen Y Jin G Zhu DEK Promoted EMT and Angiogenesis through Regulating PI3K/AKT/mTOR Pathway in Triple-Negative Breast CancerOncotarget20178589870822

24 

SB Kim R Dent SA Im M Espié S Blau AR Tan Ipatasertib plus Paclitaxel versus Placebo plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast Cancer (LOTUS): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 TrialLancet Oncol20171810304503

25 

S Kim D You Y Jeong J Yu SW Kim SJ Nam Berberine Down-Regulates IL-8 Expression through Inhibition of the EGFR/MEK/ERK Pathway in Triple-Negative Breast Cancer CellsPhytomedicine201850439

26 

AA Casique JB Montes-Alvarado M Barragán KA Larrauri-Rodríguez AP Gonzalez AD Magallón ERK Activation Modulates Invasiveness and Reactive Oxygen Species (ROS) Production in Triple Negative Breast Cancer Cell LinesCell Signal2023101110487

27 

Y Zhu X Zhu C Tang X Guan W Zhang Progress and Challenges of Immunotherapy in Triple-Negative Breast Cancer202118762188593

28 

T Ovcaricek S Frkovic E Matos B Mozina S Borstnar Triple Negative Breast Cancer - Prognostic Factors and SurvivalRad Oncol20114514652

29 

M Greenwell P Rahman Medicinal Plants: Their Use in Anticancer TreatmentInt J Pharm Sci Res2015610410315

30 

P Cosme AB Rodríguez J Espino M Garrido Plant Phenolics: Bioavailability as a Key Determinant of Their Potential Health-Promoting ApplicationsAntioxidants20209121263

31 

Z Habli G Toumieh M Fatfat ON Rahal H Gali-Muhtasib Emerging Cytotoxic Alkaloids in the Battle against Cancer: Overview of Molecular MechanismsMolecules2017222250

32 

KL Hermoni M Khanin M Danilenko G Zango Y Amosi J Levy The Anti-Cancer Effects of Carotenoids and Other Phytonutrients Resides in Their Combined ActivityArch Biochem Biophys20155722835

33 

V Shrihastini P Muthuramalingam S Adarshan M Sujitha JT Chen H Shin Plant Derived Bioactive Compounds, Their Anti-Cancer Effects and In Silico Approaches as an Alternative Target Treatment Strategy for Breast Cancer: An Updated OverviewCancers202113246222

34 

S Banerjee Y Li WZ Sarkar Multi-Targeted Therapy of Cancer by GenisteinCancer Lett2008269222642

35 

M Russo GL Russo M Daglia PD Kasi S Ravi SF Nabavi Understanding Genistein in Cancer: The “Good” and the “Bad” Effects: A ReviewFood Chem2016196589600

36 

C Spagnuolo GL Russo IE Orhan S Habtemariam M Daglia A Sureda Genistein and Cancer: Current Status, Challenges, and Future DirectionsAdv Nutr20156440819

37 

S Hosseinzadeh A Jafarikukhdan A Hosseini R Armand The Application of Medicinal Plants in Traditional and Modern Medicine: A Review of Thymus VulgarisInt J Clin Med201560963542

38 

GM Cragg PG Grothaus DJ Newman Impact of Natural Products on Developing New Anti-Cancer AgentsChem Rev20091097301243

39 

Y Li S Li X Meng RY Gan JJ Zhang HB Li Dietary Natural Products for Prevention and Treatment of Breast CancerNutrients201797728

40 

ZM Shao J Wu ZZ Shen SH Barsky Genistein Exerts Multiple Suppressive Effects on Human Breast Carcinoma Cells1Cancer Res1998582148517

41 

WD Foulkes IE Smith JS Reis-Filho Triple-Negative Breast CancerN Engl J Med201036320193848

42 

H Pan W Zhou W He X Liu Q Ding L Ling Genistein Inhibits MDA-MB-231 Triple-Negative Breast Cancer Cell Growth by Inhibiting NF-κB Activity via the Notch-1 PathwayInt J Mol Med201230233743

43 

Z Li J Li B Mo C Hu H Liu H Qi Genistein Induces Cell Apoptosis in MDA-MB-231 Breast Cancer Cells via the Mitogen-Activated Protein Kinase PathwayToxicol Vitro2008227174953

44 

L Gong Y Li A Nedeljkovic-Kurepa FH Sarkar Inactivation of NF-κB by Genistein Is Mediated via Akt Signaling Pathway in Breast Cancer CellsOncogene2003223047029

45 

Y Li S Upadhyay M Bhuiyan FH Sarkar Induction of Apoptosis in Breast Cancer Cells MDA-MB-231 by GenisteinOncogene19991820316672

46 

Y Fang Q Zhang X Wang X Yang X Wang Z Huang Quantitative Phosphoproteomics Reveals Genistein as a Modulator of Cell Cycle and DNA Damage Response Pathways in Triple-Negative Breast Cancer CellsInt J Oncol2016483101628

47 

P Chatterjee S Banerjee Evaluating Chemotherapeutic Potential of Soya-Isoflavonoids against High Penetrance Genes in Triple-Negative Breast CancerJ Biomol Struct Dyn20234215812544

48 

X Sun M Wang M Wang X Yu J Guo T Sun Metabolic Reprogramming in Triple-Negative Breast CancerFront Oncol202010428

49 

S L Guerrero-Rodríguez C Mata-Cruz S M Pérez-Tapia M A Velasco-Velázquez Role of CD36 in Cancer Progression, Stemness, and TargetingFront Cell Dev Biol202212121605

50 

B Wang N Yan D Wu Y Dou Z Liu X Hu Combination Inhibition of Triple-Negative Breast Cancer Cell Growth with CD36 siRNA-Loaded DNA Nanoprism and GenisteinNanotechnol20213239

51 

G Higgs F Slack The Multiple Roles of microRNA-155 in OncogenesisJ Clin Bioinform20133117

52 

W Kong L He EJ Richards S Challa CX Xu J Permuth-Wey Upregulation of miRNA-155 Promotes Tumour Angiogenesis by Targeting VHL and Is Associated with Poor Prognosis and Triple-Negative Breast CancerOncogene201433667989

53 

C De La Parra L Castillo-Pichardo A Cruz-Collazo L Cubano R Redis G Calin Soy Isoflavone Genistein-Mediated Downregulation of miR-155 Contributes to the Anticancer Effects of GenisteinNutr Cancer201668115464

54 

Y Li SM Meeran SN Patel H Chen TM Hardy TO Tollefsbol Epigenetic Reactivation of Estrogen Receptor-α (ERα) by Genistein Enhances Hormonal Therapy Sensitivity in ERα-Negative Breast CancerMol Cancer201312119

55 

MG Donovan OI Selmin TC Doetschman DF Romagnolo Epigenetic Activation of BRCA1 by Genistein In Vivo and Triple Negative Breast Cancer Cells Linked to Antagonism toward Aryl Hydrocarbon ReceptorNutrients201911112559

56 

H Nakagawa D Yamamoto Y Kiyozuka K Tsuta Y Uemura K Hioki Effects of Genistein and Synergistic Action in Combination with Eicosapentaenoic Acid on the Growth of Breast Cancer Cell LinesJ Cancer Res Clin Oncol2000126844854

57 

V Hörmann J Kumi-Diaka M Durity A Rathinavelu Anticancer Activities of Genistein-Topotecan Combination in Prostate Cancer CellsJ Cell Mol Med2012161126316

58 

S Kaushik H Shyam R Sharma AK Balapure Genistein Synergizes Centchroman Action in Human Breast Cancer CellsIndian J Pharma201648663742

59 

A Maginnes RK Owusu-Apenten Methotrexate Combination Effects with Genistein and Daidzein on MDA-MB-231 Breast Cancer Cell ViabilityJ Appl Life Sci Int201713119

60 

J T Hwang YK Lee JI Shin OJ Park Anti-Inflammatory and Anticarcinogenic Effect of Genistein Alone or in Combination with Capsaicin in TPA-Treated Rat Mammary Glands or Mammary Cancer Cell LineAnn N Y Acad Sci20091171141520

61 

B Paul Y Li TO Tollefsbol The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic RegulationInt J Mol Sci20181961754

62 

R Ismail-Khan MM Bui A Review of Triple-Negative Breast CancerCancer Control20101731736

63 

VS Jamdade N Sethi NA Mundhe P Kumar M Lahkar N Sinha Therapeutic Targets of Triple-Negative Breast Cancer: A ReviewBr J Pharmacol201517217422837

64 

J Sharifi-Rad C Quispe M Imran A Rauf M Nadeem T A Gondal An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health BenefitsOxid Med Cell Longev202120213268136

65 

Q Dai XO Shu JF Potter JD Kushi LH Teas Population-Based Case-Control Study of Soyfood Intake and Breast Cancer Risk in ShanghaiBr J Cancer20018533728

66 

M Messina WM Stevens JW Lampe Addressing the Soy and Breast Cancer Relationship: Review, Commentary, and Workshop ProceedingsJ Natl Cancer Inst20069818127584



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.